The impact of prophylactic antiviral agents and statin administration on graft longevity in kidney allograft recipients

References

• Fellström, B. Impact and management of hyperlipidemia posttransplantation. Transplantation 2000, 70, SS51–SS57.
   Google Scholar
• Davis, CL. (1999). Post-transplant infections. In: Schrier, R.W. ed Atlas of diseases of the kidney. 1st ed. Portland: Blackwell Science Inc, 10.3–10.39.
   Google Scholar
• Weikert, B.C., Blumberg, E.A. Viral infection after renal transplantation: surveillance and management. Clin J Am Soc Nephrol 2008, 3 Suppl 2, S76–S86.
   Google Scholar
• Endo, A., Kuroda, M., Tanzawa, K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976, 72, 323–326.
   PubMed Web of Science ®Google Scholar
• Istvan, E.S., Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001, 292, 1160–1164.
   PubMed Web of Science ®Google Scholar
• Palaniswamy, C., Selvaraj, D.R., Selvaraj, T., Sukhija, R. Mechanisms underlying pleiotropic effects of statins. Am J Ther 2010, 17, 75–78.
   Google Scholar
• Rahal, E.A., Chakhtoura, M., Abu Dargham, R., Khauli, R.B., Medawar, W., Abdelnoor, A.M. Advantages of sirolimus in a calcineurin-inhibitor minimization protocol for the immunosuppressive management of kidney allograft recipients. ISRN Immunology 2011.
   Google Scholar
• Abdelnoor, A.M., Daghir, J.T. Detection of IgG and IgM anti-Cytomegalovirus antibodies in a selected population in Lebanon. Leb Sci Bull 1985, 1, 115–119.
   Google Scholar
• Seale, H., MacIntyre, C.R., Gidding, H.F., Backhouse, J.L., Dwyer, D.E., Gilbert, L. National serosurvey of Cytomegalovirus in Australia. Clin Vaccine Immunol 2006, 13, 1181–1184.
   PubMed Web of Science ®Google Scholar
• Staras, S.A., Dollard, S.C., Radford, K.W., Flanders, W.D., Pass, R.F., Cannon, M.J. Seroprevalence of Cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis 2006, 43, 1143–1151.
   PubMed Web of Science ®Google Scholar
• Brennan, D.C. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001, 12, 848–855.
   PubMed Web of Science ®Google Scholar
• Sia, I.G., Patel, R. New strategies for prevention and therapy of Cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000, 13, 83–121.
   PubMed Web of Science ®Google Scholar
• Ho, M. Advances in understanding Cytomegalovirus infection after transplantation. Transplant Proc 1994, 26, 7–11.
   PubMedGoogle Scholar
• Reyes, J., Abu-Elmagd, K., Tzakis, A., Nour, B., Casavilla, A., Kusne, S., Green, M., Alessiani, M., Jain, A., Fung, J.J. Infectious complications after human small bowel transplantation. Transplant Proc 1992, 24, 1249–1250.
   Google Scholar
• Reinke, P., Prösch, S., Kern, F., Volk, H.D. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis 1999, 1, 157–164.
   PubMedGoogle Scholar
• Rook, A.H. Interactions of cytomegalovirus with the human immune system. Rev Infect Dis 1988, 10 Suppl 3, S460–S467.
   PubMedGoogle Scholar
• Gómez, E., Laurés, A., Baltar, J.M., Melón, S., Díez, B., de Oña, M. Cytomegalovirus replication and “herpesvirus burden” as risk factor of cardiovascular events in the first year after renal transplantation. Transplant Proc 2005, 37, 3760–3763.
   PubMed Web of Science ®Google Scholar
• Chade, A.R., Lerman, A., Lerman, L.O. Kidney in early atherosclerosis. Hypertension 2005, 45, 1042–1049.
   PubMed Web of Science ®Google Scholar
• Wang, H.R., Li, J.J., Huang, C.X., Jiang, H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 2005, 353, 53–60.
   PubMed Web of Science ®Google Scholar
• Kleemann, R., Verschuren, L., de Rooij, B.J., Lindeman, J., de Maat, M.M., Szalai, A.J., Princen, H.M., Kooistra, T. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004, 103, 4188–4194.
   PubMed Web of Science ®Google Scholar
• Weber, C., Erl, W., Weber, P.C. Lovastatin induces differentiation of Mono Mac 6 cells. Cell Biochem Funct 1995, 13, 273–277.
   PubMedGoogle Scholar
• Chakrabarti, R., Engleman, E.G. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biol Chem 1991, 266, 12216–12222.
   PubMed Web of Science ®Google Scholar
• Cutts, J.L., Bankhurst, A.D. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 1990, 145, 244–252.
   PubMed Web of Science ®Google Scholar
• Rudich, S.M., Mongini, P.K., Perez, R.V., Katznelson, S. HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Transplant Proc 1998, 30, 992–995.
   PubMed Web of Science ®Google Scholar
• Katznelson, S., Wang, X.M., Chia, D., Ozawa, M., Zhong, H.P., Hirata, M., Terasaki, P.I., Kobashigawa, J.A. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 1998, 17, 335–340.
   Google Scholar
• Rosenson, R.S., Tangney, C.C., Casey, L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999, 353, 983–984.
   PubMed Web of Science ®Google Scholar
• Romano, M., Diomede, L., Sironi, M., Massimiliano, L., Sottocorno, M., Polentarutti, N., Guglielmotti, A., Albani, D., Bruno, A., Fruscella, P., Salmona, M., Vecchi, A., Pinza, M., Mantovani, A. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000, 80, 1095–1100.
   PubMed Web of Science ®Google Scholar
• Kothe, H., Dalhoff, K., Rupp, J., Müller, A., Kreuzer, J., Maass, M., Katus, H.A. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000, 101, 1760–1763.
   PubMed Web of Science ®Google Scholar
• Asher, J., Houston, M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007, 9, 622–628.
   PubMedGoogle Scholar
• Liu, L., Moesner, P., Kovach, N.L., Bailey, R., Hamilton, A.D., Sebti, S.M., Harlan, J.M. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J Biol Chem 1999, 274, 33334–33340.
   Google Scholar
• Weber, C., Erl, W., Weber, K.S., Weber, P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997, 30, 1212–1217.
   PubMed Web of Science ®Google Scholar
• Kwak, B., Mulhaupt, F., Myit, S., Mach, F. Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6, 1399–1402.
   PubMed Web of Science ®Google Scholar
• El-Haibi, C., Rahal, E., Khauli, R.B., Abdelnoor, A.M. Effect of atorvastatin on antibody, interleukin-4 and gamma-interferon production in mice immunized with egg albumin. Immunopharmacol Immunotoxicol 2006, 28, 459–470.
   PubMed Web of Science ®Google Scholar
• Abdelnoor, A.M., Ajib, R., Chakhtoura, M., Daouk, M., Medawar, W., Uwaydah, M., Sawah, S.I., Khauli, R.B. Influence of HLA disparity, immunosuppressive regimen used, and type of kidney allograft on production of anti-HLA class-I antibodies after transplant and occurrence of rejection. Immunopharmacol Immunotoxicol 2009, 31, 83–87.
   PubMed Web of Science ®Google Scholar